ES3018944T3 - Potency assay - Google Patents

Potency assay Download PDF

Info

Publication number
ES3018944T3
ES3018944T3 ES22150277T ES22150277T ES3018944T3 ES 3018944 T3 ES3018944 T3 ES 3018944T3 ES 22150277 T ES22150277 T ES 22150277T ES 22150277 T ES22150277 T ES 22150277T ES 3018944 T3 ES3018944 T3 ES 3018944T3
Authority
ES
Spain
Prior art keywords
cells
mpc
mpcs
culture medium
tgfp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22150277T
Other languages
English (en)
Spanish (es)
Inventor
Paul Simmons
Colby Suire
Fiona See
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901605A external-priority patent/AU2015901605A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Application granted granted Critical
Publication of ES3018944T3 publication Critical patent/ES3018944T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
ES22150277T 2015-05-05 2016-05-04 Potency assay Active ES3018944T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2015901605A AU2015901605A0 (en) 2015-05-05 Potency assay

Publications (1)

Publication Number Publication Date
ES3018944T3 true ES3018944T3 (en) 2025-05-19

Family

ID=56087237

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22150277T Active ES3018944T3 (en) 2015-05-05 2016-05-04 Potency assay
ES16725775T Active ES2911266T3 (es) 2015-05-05 2016-05-04 Ensayo de potencia

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16725775T Active ES2911266T3 (es) 2015-05-05 2016-05-04 Ensayo de potencia

Country Status (9)

Country Link
US (3) US11795435B2 (https=)
EP (2) EP3292199B1 (https=)
JP (4) JP6797833B2 (https=)
KR (2) KR102582602B1 (https=)
CN (2) CN115141872A (https=)
AU (3) AU2016258980B2 (https=)
CA (1) CA2984987C (https=)
ES (2) ES3018944T3 (https=)
WO (1) WO2016177805A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CA3112505C (en) * 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
JP2022515916A (ja) * 2019-01-02 2022-02-22 メゾブラスト・インターナショナル・エスアーエールエル 腰痛を治療するための方法
US20230221303A1 (en) * 2020-04-20 2023-07-13 Longeveron Inc. Potency assay
KR20240101473A (ko) * 2022-12-23 2024-07-02 주식회사 강스템바이오텍 연골 분화능이 증진된 줄기세포의 선별 방법 및 이를 포함하는 세포 치료제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
WO2001097872A1 (en) 2000-06-22 2001-12-27 Austin Sam L Bioadhesive compositions and methods of preparation and use
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
KR100802011B1 (ko) * 2005-08-10 2008-02-12 인하대학교 산학협력단 층분리배양법을 이용한 골수에서의 중간엽 줄기세포분리방법
JP2011196840A (ja) * 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法
BE1020528A3 (fr) * 2011-10-11 2013-12-03 Bone Therapeutics Sa Utilisations du facteur de croissance et differenciation 8 (gdf 8).
SG11201509430WA (en) 2013-05-16 2015-12-30 Agency Science Tech & Res Heparan sulphates
KR20150016117A (ko) 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
CN103990181B (zh) * 2014-05-26 2015-07-08 中国人民解放军第四军医大学 一种具有诱导活性微载体-细胞复合物的制备方法及其应用

Also Published As

Publication number Publication date
AU2016258980A1 (en) 2017-11-23
KR102885856B1 (ko) 2025-11-14
HK1247236A1 (zh) 2018-09-21
EP3292199B1 (en) 2022-01-12
EP3292199A1 (en) 2018-03-14
CA2984987C (en) 2023-10-10
JP7754893B2 (ja) 2025-10-15
JP2026012704A (ja) 2026-01-27
JP2021036892A (ja) 2021-03-11
CN115141872A (zh) 2022-10-04
AU2022203140B2 (en) 2025-04-10
WO2016177805A1 (en) 2016-11-10
JP2018517900A (ja) 2018-07-05
JP2023159260A (ja) 2023-10-31
AU2025205043A1 (en) 2025-07-24
JP7335222B2 (ja) 2023-08-29
AU2016258980B2 (en) 2022-02-17
KR20230140604A (ko) 2023-10-06
CA2984987A1 (en) 2016-11-10
BR112017023660A2 (pt) 2018-07-17
US20240409898A1 (en) 2024-12-12
ES2911266T3 (es) 2022-05-18
JP6797833B2 (ja) 2020-12-09
KR20180041621A (ko) 2018-04-24
CN107771220A (zh) 2018-03-06
US11795435B2 (en) 2023-10-24
EP4015624B1 (en) 2025-02-19
EP4015624A1 (en) 2022-06-22
CN107771220B (zh) 2022-07-05
KR102582602B1 (ko) 2023-09-25
US20240076621A1 (en) 2024-03-07
AU2022203140A1 (en) 2022-06-02
US20200140822A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
US20240409898A1 (en) Potency assay
ES2923016T3 (es) Células precursoras mesenquimales TNAP+ para el tratamiento de enfermedades del tejido conectivo
AU2020204805B2 (en) Method for treating lower back pain
ES2676886T3 (es) Método para aumentar la función osteoblástica
BR112017023660B1 (pt) Método para selecionar células precursoras de linhagem mesenquimal ou células-tronco humanas, composições e uso das mesmas
HK1247236B (en) Potency assay
Hofer Traumatized muscle-derived multipotent progenitor cells: Pro-angiogenic activity, promotion of nerve growth, and osteogenic differentiation
Beaumont Dental pulp stem cells and leukocyte-and platelet-rich fibrin as candidate therapies for articular cartilage and tendon repair
Graceffa Macromolecular crowding for chondrogenic phenotype maintenance and stem cell differentiation
Vigano Mesenchymal Stem Cells for the treatment of osteoarthritis and tendinopathy
Martin Promoting Cartilage Stem Cell Activity to Improve Recovery from Joint Fracture
Rathod Investigating Therapeutic Strategies for Treatment of Osteoarthritis in the Knee Joint